Ascendis Pharma Reports Strong Q1 Profit & $187.5M PRV Sale; Redeems $575M Convertible Notes

summarizeSummary

Ascendis Pharma reported a significant swing to net profit in Q1 2026, driven by strong YORVIPATH sales and deferred tax asset recognition. The company also announced the sale of a Rare Pediatric Disease Priority Review Voucher for $187.5 million and completed the redemption of $575 million in convertible notes.

check_boxKey Events

• Strong Q1 2026 Financial Performance

  The company reported a net profit of €629.3 million for Q1 2026, a significant improvement from a net loss of €94.6 million in Q1 2025. Revenue increased to €246.6 million from €100.954 million year-over-year, primarily driven by continued global sales growth of YORVIPATH. The net profit was largely boosted by the recognition of €679.0 million in deferred tax assets.

• Sale of Rare Pediatric Disease Priority Review Voucher (PRV)

  Subsequent to the quarter end, on May 6, 2026, Ascendis Pharma entered into an agreement to sell its PRV for $187.5 million. This PRV was awarded following the FDA approval of YUVIWEL in February 2026, providing a significant cash inflow.

• Redemption of $575 Million Convertible Notes

  On May 6, 2026, the company completed the optional redemption of its $575 million 2.25% convertible notes due 2028. All noteholders converted their notes, resulting in the delivery of 3,635,813 ordinary shares and the settlement of €733.1 million in liabilities.

• Share Repurchase Program Update

  Under the $120 million share repurchase program authorized on January 9, 2026, the company repurchased 254,027 ordinary shares for $60.0 million in March 2026, with $60.0 million remaining for future repurchases.

auto_awesomeAnalysis

Ascendis Pharma reported a significant financial turnaround in Q1 2026, swinging to a net profit of €629.3 million from a net loss of €94.6 million in the prior year, primarily driven by strong YORVIPATH sales and the recognition of €679.0 million in deferred tax assets. The company also announced the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $187.5 million, a substantial cash inflow. Furthermore, Ascendis completed the redemption of its $575 million convertible notes due 2028, settling the liability by issuing 3,635,813 ordinary shares, which removes a significant debt obligation and potential future dilution uncertainty. These financial and strategic moves, coupled with positive clinical updates for TransCon CNP, reinforce the company's strong operational and financial trajectory.